Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News from Boston Scientific

Boston Scientific Reports 16 Deaths Linked To Defibrillator Lead Issue

The Food and Drug Administration (FDA) said on Wednesday it is monitoring a potential safety issue involving Boston Scientific Corporation’s (NYSE:BSX) ENDOTAK RELIANCE defibrillation leads, following a letter from the company alerting healthcare providers of possible reduced shock efficacy.

Benzinga

FDA flags problems with two Boston Scientific heart devices tied to injuries and deaths

U.S. health officials have issued warnings on two separate Boston Scientific heart devices recently linked to injuries and deaths

The Independent UK

Boston Scientific Reports Higher Profit Margins In Q2, Lifts Guidance

Stronger‑than‑expected sales and raised full‑year guidance underscore Boston Scientific Corporation‘s (NYSE:BSX) momentum—and hint at where its next product wins may come.

Benzinga

From analysis to the latest developments in health,
read the most diverse news in one place.

How Unusual Options Standout Boston Scientific (BSX) is Signaling a Statistical Edge

BSX stock may extend its solid performance as options activity and historical patterns suggest a bullish setup with favorable short-term odds.

Barchart

What to Expect From Boston Scientific's Next Quarterly Earnings Report

Boston Scientific is set to announce its second-quarter results later this month, and analysts anticipate double-digit earnings growth.

Barchart

How Is Boston Scientific's Stock Performance Compared to Other Medical Device Stocks?

Due to Boston Scientific's strong performance relative to its industry peers over the past year, Wall Street analysts maintain a bullish outlook on the stock’s prospects.

Barchart

Are Wall Street Analysts Predicting Boston Scientific Stock Will Climb or Sink?

Boston Scientific has outpaced the broader market over the past year and analysts are highly upbeat about its future prospects.

Barchart

Read news from The Economist, FT, and more,
with one subscription

Women left waiting for share of $405m implant payout

A years-long wait for compensation continues for women injured from pelvic mesh implants with delays blamed on difficulty in obtaining medical records.

AAP

3 Stocks Lifting 2025 Guidance Despite Market Jitters

See these three stocks that beat on earnings in Q1 and raised their guidance for the rest of 2025. These stocks are signaling strength amid tough conditions.

MarketBeat

The Sentiment Genome: BSX Stock Could Be Entering a High-Probability Setup

With the market signaling a hot deck, risk-tolerant speculators will want to keep close tabs on BSX stock over the next week.

Barchart

Is Wall Street Bullish or Bearish on Boston Scientific Stock?

Boston Scientific has notably outpaced the broader market over the past year. As a result, analysts are holding a highly optimistic outlook for its future prospects.

Barchart

Are Wall Street Analysts Bullish on Boston Scientific Stock?

Boston Scientific has significantly outperformed the broader market over the past year, and analysts maintain a very bullish view on its outlook.

Barchart

Up 45% YTD, Should You Buy This Outperforming Healthcare Stock?

Boston Scientific shows impressive growth in Q3 results, garnering bullish analyst support despite clinical trial setbacks.

Barchart

Earnings Preview: What To Expect from Boston Scientific's Report

With Boston Scientific gearing up to release its third-quarter earnings later this month, analysts expect double-digit earnings growth.

Barchart

Get all your
news in one place.

100's of premium titles.
One news app.

Barchart

3 'Strong Buy' Stocks to Grab Now for More Gains

For investors looking to add some high-potential stocks to their portfolio, here are three top-rated opportunities to consider now.

Barchart

Is Boston Scientific Stock Outperforming the Nasdaq?

Boston Scientific has outperformed the Nasdaq Composite over the past year, and analysts remain bullish on the stock’s prospects.

The Independent UK

'I'm on morphine patches every day': Woman still waiting for vaginal mesh removal four years later

‘I used to walk everywhere, but now I just potter around the house. I no longer walk to the shops,’ June Dunne tells Maya Oppenheim

Evening Standard

Women harmed by vaginal mesh in England get payout

The amount of the financial settlement has not been made public, although it is expected millions have been paid out

Get all your
news in one place.

100's of premium titles.
One news app.

The Independent UK

140 women win payouts for vaginal mesh complications

Women claimed the implants caused infection, bleeding, chronic pain, bladder and bowel perforations, and problems urinating

The Guardian - UK

140 women in England receive payout for vaginal mesh implant complications

Settlement from first successful group claim in England expected to total millions of pounds, but size of payments unknown

Barchart

What Are Wall Street Analysts' Target Price for Boston Scientific Stock?

Boston Scientific has outperformed the broader market over the past year, and analysts remain bullish about the stock’s prospects.

Fortune

How Boston Scientific's digital and IT boss upgraded her team from order takers to strategic thinkers

The $110 billion medical devices company now has a digital leader who sits on the executive management board of every division, every region, and every business function.

Barchart

Boston Scientific's Quarterly Earnings Preview: What You Need to Know

Boston Scientific is expected to report its second-quarter earnings results this month, and Wall Street analysts expect a single-digit profit growth.

Barchart

Is Boston Scientific Stock Outperforming the S&P 500?

Boston Scientific recently reached an all-time high, outperforming the S&P 500 Index, with Wall Street analysts remaining bullish about the stock’s prospects.

Barchart

Boston Scientific Stock: Is Wall Street Bullish or Bearish?

Boston Scientific has significantly outperformed the broader market YTD, and Wall Street analysts are still bullish about the stock’s prospects.

1 2 3 4

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Food and Drug Administration

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.